Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tracon Pharmaceuticals Inc.
This study is being performed to evaluate the safety and tolerability of TRC102 in combination with Alimta. In addition to safety, this study will also evaluate pharmacokinetics and tumor response.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient has given informed consent
The patient is willing and able to abide by the protocol
The patient has cancer and curative therapy is unavailable or standard therapy has failed
The patient is at least 18 years of age
The patient has adequate ability to perform activities of daily living
The patient has recovered from significant toxicities of previous therapy
The patient has adequate organ function as assessed by laboratory testing
You may not be if
The patient has had prior treatment with high-dose chemotherapy requiring stem cell rescue
The patient is currently on treatment on another therapeutic clinical trial or has received an investigational drug within 4 weeks prior to first dose on this study
The patient has had prior surgery, radiation or systemic therapy within 4 weeks of starting the study
The patient has a history of CNS cancer
The patient has an unstable medical condition including (not limited to) cardiac disease, HIV/AIDS, history of stroke, hepatitis or significant paricardial, pleural or peritoneal effusion
The patient is pregnant or breastfeeding
Clareo Health | Study of TRC102 in Combination With Pemetrexed in Cancer Patients
